



http://www.elsevier.com/locate/jiph

IN THIS ISSUE

Lung cancer guidelines supplement editor

The management of non-small cell lung cancer is rapidly evolving toward personalized therapy based on molecular markers. This advancement was facilitated by the development of targeted therapy that was proven efficacious in clinical trials. The availability of newer therapies and the incorporation of markers in the treatment decision will have impact on the standard of care, not in that setting only but also in the subsequent lines of ther-

The Saudi Lung Cancer Guidelines published in this Journal are the result of efforts by multidisciplinary team members representing Saudi Lung Cancer Group in Saudi Thoracic Society (STS) and Saudi Oncology Society (SOS) and representing various tertiary institutions in the Kingdom. These guidelines incorporated the latest evidences emerged from recent trials and took into account any relevant regional issues.

Many thanks to all members of this group and we are looking to any constructive feedback from our

Saudi Lung Cancer Guidelines Group:

Dr. Abdulrahman Al Hadab, King Saud bin Abdulaziz University for Health Sciences, Riyadh, KSA

Dr. Adnan Hebshi, King Faisal Specialist Hospital & Research Center, Riyadh, KSA

Dr. Ahmed Abdulwarith, King Fahad Specialist Hospital, Dammam, KSA

Dr. Ahmed Bamousa, Riyadh Military Hospital, Riyadh, KSA

Dr. Ahmed Saadeddin, Riyadh Military Hospital, Riyadh, KSA

Dr. Ashwaq Al Olayan, King Saud bin Abdulaziz University for Health Sciences, Riyadh, KSA

Dr. Azzam Khankan, King Saud bin Abdulaziz University for Health Sciences, KSA

Dr. Foad Al Dayel, King Faisal Specialist Hospital & Research Center, Riyadh, KSA

Dr. Hamed Al Husaini, King Faisal Specialist Hospital & Research Center, Riyadh, KSA

Dr. Hamdan Al Jahdali, King Saud bin Abdulaziz University for Health Sciences, Riyadh, KSA

Dr. Hana Bamefleh, King Saud bin Abdulaziz University for Health Sciences, Riyadh, KSA

Dr. Khalid Al Kattan, Al Faisal University, Riyadh,

Dr. Loutfi, Shukri, King Saud bin Abdulaziz University for Health Sciences, Riyadh, KSA

Dr. M. Hasan Rajab, Al Faisal University, Riyadh, KSA

Dr. Sara Al Ghanim, King Saud bin Abdulaziz University for Health Sciences, Riyadh, KSA

Dr. Turki Al Fayae, King Abdulaziz Medical City, Princess Noorah Oncology Center, Jeddah, KSA Dr. Yasir Bahadur, King Faisal Specialist Hospital & Research Center, Jeddah, KSA

Abdul Rahman Jazieh (MD, MPH) Saudi Lung Cancer Group, Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia

Available online at www.sciencedirect.com

SciVerse ScienceDirect